Prevymis Evropská unie - islandština - EMA (European Medicines Agency)

prevymis

merck sharp & dohme b.v. - letermovir - cytomegalovirus sýkingar - veirueyðandi lyf til almennrar notkunar - prevymis er ætlað til að fyrirbyggja cmv (cmv) endurvakning og sjúkdómurinn í fullorðinn cmv-mótefni viðtakendur [r+] af ósamgena skurðaðgerðir stafa klefi grætt (hsct). Íhuga ætti að opinbera leiðsögn á réttri notkun af veirum.

Teriflunomide Mylan Evropská unie - islandština - EMA (European Medicines Agency)

teriflunomide mylan

mylan pharmaceuticals limited - teriflunomide - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi lyf - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Teriflunomide Accord Evropská unie - islandština - EMA (European Medicines Agency)

teriflunomide accord

accord healthcare s.l.u. - teriflunomide - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi, sérhæfður ónæmisbælandi - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Metoject Stungulyf, lausn í áfylltri sprautu 50 mg/ml Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

metoject stungulyf, lausn í áfylltri sprautu 50 mg/ml

medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltri sprautu - 50 mg/ml

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Evropská unie - islandština - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klópídógrel hýdróklóríð - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - blóðþurrðandi lyf - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Reyataz Evropská unie - islandština - EMA (European Medicines Agency)

reyataz

bristol-myers squibb pharma eeig - atazanavir (as sulfate) - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - reyataz hylki, sam-gefið með lítinn skammt rítónavír, eru ætlað til meðferðar hiv-1 sýkt fullorðna og börn sjúklingar 6 ára og eldri ásamt öðrum antiretroviral lyf (sjá kafla 4. byggt á boði veirufræðilega og klínískum gögn úr fullorðinn sjúklingar, ekkert gagn er væntanlegur í sjúklingum við stofnum þola margar próteasahemlar (stærri 4 pi stökkbreytingar). val á reyataz í meðferð upplifað fullorðna og börn sjúklingar ætti að vera byggt á einstökum veiru mótstöðu próf og sjúklings meðferð sögu (sjá kafla 4. 4 og 5. reyataz inntöku duft, sam-gefið með lítinn skammt rítónavír, er ætlað ásamt öðrum antiretroviral lyf til meðferð hiv-1 sýkt börn sjúklingar að minnsta kosti 3 mánaða aldur og vega að minnsta kosti 5 kg (sjá kafla 4. byggt á boði veirufræðilega og klínískum gögn úr fullorðinn sjúklingar, ekkert gagn er væntanlegur í sjúklingum við stofnum þola margar próteasahemlar ( 4 pi stökkbreytingar). val á reyataz í meðferð upplifað fullorðna og börn sjúklingar ætti að vera byggt á einstökum veiru mótstöðu próf og sjúklings meðferð sögu (sjá kafla 4. 4 og 5.

Seroquel Prolong Forðatafla 50 mg Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

seroquel prolong forðatafla 50 mg

cheplapharm arzneimittel gmbh - quetiapinum fúmarat - forðatafla - 50 mg

Seroquel Prolong Forðatafla 300 mg Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

seroquel prolong forðatafla 300 mg

cheplapharm arzneimittel gmbh - quetiapinum fúmarat - forðatafla - 300 mg

Seroquel Prolong Forðatafla 200 mg Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

seroquel prolong forðatafla 200 mg

cheplapharm arzneimittel gmbh - quetiapinum fúmarat - forðatafla - 200 mg

Seroquel Prolong Forðatafla 150 mg Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

seroquel prolong forðatafla 150 mg

cheplapharm arzneimittel gmbh - quetiapinum fúmarat - forðatafla - 150 mg